Entering text into the input field will update the search result below

AstraZeneca, Perrigo sign deal for rights to Entocort

Nov. 23, 2015 3:56 AM ETAstraZeneca PLC (AZN) StockAZN, PRGOBy: Yoel Minkoff, SA News Editor2 Comments
  • AstraZeneca (NYSE:AZN) has finalized plans to divest its Crohn's disease drug Entocort by selling U.S. rights to the medicine to Perrigo (NASDAQ:PRGO) for $380M.
  • The move is part of AstraZeneca's "externalization" drive, which aims to sell non-core products to help it fill a short-term revenue gap caused by older drugs, while investing in a pipeline of new medicines.
  • Entocort had U.S. sales of $89M in the first nine months of 2015.

Recommended For You

About AZN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
AZN--
AstraZeneca PLC